Cambridge Respiratory Innovations Ltd

Cambridge Respiratory Innovations’ overall aim is to develop an inexpensive COPD home health device specifically targeted at personal monitoring and treatment management. The device is simple to use and monitors normally exhaled carbon dioxide using III-V mid-infrared LEDs. The device helps COPD sufferers better manage their health and enables healthcare professionals to assess the effectiveness of treatment through periodic review of the data collected. It is hoped users will experience fewer uncontrolled exacerbations.

Cambridge Respiratory Innovations Limited (CRiL) of Swavesey, Cambridgeshire, has been awarded an SBRI Healthcare feasibility study development contract for a self-care asthma monitor using its innovative N-Tidal technology. CRiL has developed an epitaxially-grown LED-based CO2 sensor specifically to measure CO2 in respired breathing. The sensor and technology platform has been proven in COPD and this feasibility study will investigate its potential use in the reversible condition of asthma. The intention is to reduce the demands on primary care through improved management of asthma. 5.4 million people in the UK suffer from asthma, which is generally poorly diagnosed and controlled.

Cambridge Respiratory Innovations is developing both a simple, patient friendly, quantifiable asthma metric (currently absent in asthma management) and a low-cost personal medical device that would ultimately facilitate closed loop control of poorly managed asthma. The capnometer and respiration rate meter are based on a patented non-dispersive infra-red, fast acting sensor. It is anticipated that the use of the devices will increase personal disease ownership, improve medicines compliance and reduce respiratory exacerbations, minimising acute in-patient stays